EUVIMEDEUVIMED entdecken
Crossref

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States

Pojsakorn Danpanichkul iD, Kwanjit Duangsonk iD, Markos Kalligeros iD, Michael B Fallon iD, Chawinthorn Vuthithammee, Chun Wei Pan iD, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L Chen iD, Donghee Kim iD, Amit G Singal iD und 2 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Pojsakorn Danpanichkul und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA. Hauptthemen laut MEDLINE: Liver Diseases, Alcoholic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Primary liver cancer (PLC) is projected to be the third leading cause of cancer mortality in the United States in 2040. We examine the burden of PLC in the United States, stratified by sex, state and aetiological risk factors.

Methods

Data on PLC prevalence, incidence, death and disability–adjusted life years (DALYs) were extracted from the Global Burden of Disease Study 2021. Changes in these parameters were calculated using the Joinpoint regression model.

Results

There were 47,970 cases, 31,450 incident cases, 24,770 deaths and 576,920 DALYs from PLC in the United States. The highest prevalence (16,980), incidence (12,040), death (9840) and DALYs (213,410) from PLC were due to chronic hepatitis C virus infection. From 2000 to 2021, PLC incidences increased by 141%, and PLC deaths increased by 136%. Age–standardised incidence rates (ASIRs) and death rates (ASDRs) per 100,000 population for PLC increased, primarily driven by alcohol–related liver disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) and metabolic dysfunction–associated steatotic liver disease (MASLD) (ASIR: APC: +2.32%; ASDR: APC: +2.04%).

Conclusion

The burden of PLC in the United States has risen in the past two decades, driven mainly by ALD and followed by MASLD. These findings offer policymakers an accurate assessment of the PLC burden and emphasise the need for targeted risk factor mitigation, especially regarding alcohol related policy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Diseases, AlcoholicMetabolic DiseasesFatty LiverLiver NeoplasmsUnited StatesHumansDisability-Adjusted Life YearsAdultMiddle AgedAged

Stichwörter der Autor:innen

addictionalcoholepidemiologygastrointestinal cancermetabolic dysfunction‐associated steatohepatitisnonalcoholic fatty liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
  • Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
  • Department of Internal Medicine, Banner University Medical Center, Phoenix, Arizona, USA.
  • Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B Fallon, Chun Wei Pan, Vincent L Chen, Donghee Kim, Amit G Singal, Ju Dong Yang, Karn Wijarnpreecha

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Danpanichkul, P., Duangsonk, K., Kalligeros, M., Fallon, M. B., Vuthithammee, C., Pan, C. W., Saokhieo, P., Derrick, W., Pang, Y., Chen, V. L., Kim, D., Singal, A. G., Yang, J. D., & Wijarnpreecha, K. (2025). Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18473

Vancouver

Danpanichkul P, Duangsonk K, Kalligeros M, Fallon MB, Vuthithammee C, Pan CW, et al. Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18473

BibTeX
@article{Danpanichkul2025,
  author = {Danpanichkul, Pojsakorn and Duangsonk, Kwanjit and Kalligeros, Markos and Fallon, Michael B and Vuthithammee, Chawinthorn and Pan, Chun Wei and Saokhieo, Preenapun and Derrick, William and Pang, Yanfang and Chen, Vincent L and Kim, Donghee and Singal, Amit G and Yang, Ju Dong and Wijarnpreecha, Karn},
  title = {Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18473}
}
Kostenlos starten →